|
TG Therapeutics, Inc. Announces Presentation of Interim Results From Its Phase …
NASDAQ (press release) NEW YORK, June 3, 2013 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. ( TGTX ) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients with rituximab relapsed and/or refractory Non-Hodgkin’s … |
TG Therapeutics , Inc . Announces Presentation of Interim Results From Its … – MarketWatch
|
TG Therapeutics , Inc . Announces Presentation of Interim Results From Its …
MarketWatch TG Therapeutics, Inc. (TGTX) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients with rituximab relapsed and/or refractory Non-Hodgkin’s Lymphoma (NHL), presented at the American Society … |
The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for … – 7thSpace Interactive (press release)
The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for …7thSpace Interactive (press release)We further hypothesized that treatment with cyclosporine A, a Pgp1 inhibitor, would render cells more sensitive to treatment with corticost…
INTERNATIONAL > Human rights body calls on int'l sister bodies for … – Hurriyet Daily News
|
INTERNATIONAL > Human rights body calls on int’l sister bodies for …
Hurriyet Daily News When asked whether he was in a position to confirm these reports, Bakkalcı referred to the written statement by the TİHV which said, “There are extremely persuasive and strong claims about brain death of a young person of ours in Ankara as of last … |
Scientists develop new method for finding therapeutic antibodies – domain-B
Scientists develop new method for finding therapeutic antibodiesdomain-BScientists at The Scripps Research Institute (TSRI) at La Jolla, California, have devised a powerful new technique for finding antibodies that have a desired biological effect. Ant…
Uganda: New Hope for Heart Patients – AllAfrica.com
Uganda: New Hope for Heart PatientsAllAfrica.comSeven-year-old Joshua Mukalazi is a heart patient and very lucky to be the second beneficiary of Keith Heart Foundation (KHF). He received sponsorship for treatment in India for the second time after Mula…
Compensation sum insulting to acid attack victim in Mumbai: Sushma Swaraj – Times of India
Compensation sum insulting to acid attack victim in Mumbai: Sushma SwarajTimes of IndiaShe suffered grievous injuries which included collapse of her right lung, damage to her left lung, oesophagus, windpipe, trachea and other vital organs. Preeti succu…
In death, Noam from Modiin Illit saves life of Yakoub from Bethlehem – Israel Hayom
|
In death, Noam from Modiin Illit saves life of Yakoub from Bethlehem
Israel Hayom Despite great efforts, the doctors at Sheba Medical Center in Ramat Gan were unable to save Noam, who had sustained severe head injuries resulting in irreversible brain death. The toddler’s family consulted with various rabbis, who supported their … Jewish kidney donation saves Palestinian boyJerusalem Post |
Ontario Man Bikes Across Canada Starting Monday to Promote Organ Donation … – Marketwire (press release)
|
Ontario Man Bikes Across Canada Starting Monday to Promote Organ Donation …
Marketwire (press release) I’m biking to encourage everyone I meet on the road to have the courage to become a registered organ donor,” said Cayse Ruiter. Cayse will bike from Tofino, British Columbia to St. John’s, Newfoundland over two months in order to raise awareness about … |
Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor … – PharmiWeb.com (press release)
|
Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor …
PharmiWeb.com (press release) Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor® (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior … Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor …SYS-CON Media (press release) NOVARTIS AG : pivotal Phase III trial shows Afinitor® significantly delays …4-traders (press release) |